Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855924 | 0.93 | GRIN2D (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10914880 | 0.91 | DNM1 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL12997286 | 0.91 | DNM1 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29234768 | 0.91 | GRIN2D (0.31) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL254457 | 0.75 | — | — | |
| SCHEMBL253950 | 0.75 | — | — | |
| SCHEMBL13361696 | 0.75 | — | — | |
| SCHEMBL8566999 | 0.75 | — | — | |
| SCHEMBL18322828 | 0.75 | — | — | |
| SCHEMBL506092 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605461-B2 | Hydrogel compositions and uses thereof | Shoichet, Molly Sandra (CA) | 2026-04-21 | — | — | US | disclosed |
| CN-114466869-B | Hydrogel composition and use thereof | 莫莉·桑德拉·萧伊凯特 | 2024-03-19 | — | — | CN | disclosed |
| US-20230364025-A1 | PROTEIN-RELEASE SYSTEM FOR SUSTAINED RELEASE OF PROTEINS | ISAACS BERNAL DANIELA FERNANDA (CA) | 2023-11-16 | — | — | US | disclosed |
| US-20230133656-A1 | HYDROGEL COMPOSITIONS AND USES THEREOF | SHOICHET, MOLLY SANDRA (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20230133656-A1 | HYDROGEL COMPOSITIONS AND USES THEREOF | SHOICHET, MOLLY SANDRA (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20230133656-A1 | HYDROGEL COMPOSITIONS AND USES THEREOF | SHOICHET, MOLLY SANDRA (CA) | 2023-05-04 | — | — | US | disclosed |
| EP-3994183-A1 | HYDROGEL COMPOSITIONS AND USES THEREOF | Shoichet, Molly Sandra (CA) | 2022-05-11 | — | — | EP | disclosed |
| CN-114466869-A | Hydrogel composition and use thereof | 莫莉·桑德拉·萧伊凯特 | 2022-05-10 | — | — | CN | disclosed |
| WO-2021000050-A1 | HYDROGEL COMPOSITIONS AND USES THEREOF | SHOICHET MOLLY SANDRA (CA) | 2021-01-07 | — | — | WO | disclosed |
| US-9765071-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2005051324-A2 | HYDROXYLAMINE AND OXIME SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051317-A2 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| US-6812349-B2 | MATERIALS FOR SYNTHESIS PEPTIC ULCER MEDICAMENTS; SUCH AS 2-CYANO-4,5-DIMETHYL-1-N-(PENTAN-2-ON-5-YL)IMIDAZOLE | ALTANA PHARMA AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-6716990-B2 | TREATMENT OF PEPTIC ULCERS | ALTANA PHARMA AG (DE) | 2004-04-06 | — | — | US | disclosed |
| US-20040059127-A1 | Process and intermediates for the preparation of imidazopyridines | BYK GULDEN FABRIK LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2004-03-25 | — | — | US | disclosed |
| US-20030004358-A1 | Process and intermediates for the preparation of imidazopyridines | ALTANA PHARMA AG (DE) | 2003-01-02 | — | — | US | disclosed |
| EP-1250335-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF IMIDAZOPYRIDINES | ALTANA Pharma AG (DE) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001051486-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF IMIDAZOPYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
| US-4167632-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1979-09-11 | — | — | US | disclosed |
| US-4122265-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133656-A1 | HYDROGEL COMPOSITIONS AND USES THEREOF | CD44, UACA, ALDH1A2 | GRIN2D 1935/4885GRIN3B 3053/4885GRIN1 2476/4885 |
| US-20030004358-A1 | Process and intermediates for the preparation of imidazopyridines | CYP3A4, CYP1A1, CYP1A2 | GRIN2D 2345/4885GRIN3B 2708/4885GRIN1 1351/4885 |
| US-20040059127-A1 | Process and intermediates for the preparation of imidazopyridines | CYP3A4, CYP1A2, CYP1A1 | GRIN2D 2978/4885GRIN3B 3087/4885GRIN1 1696/4885 |
| US-12605461-B2 | Hydrogel compositions and uses thereof | CD44, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1 | GRIN2D 880/4885GRIN3B 2054/4885GRIN1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.